Your session is about to expire
← Back to Search
Tocilizumab + Atezolizumab for Non-Small Cell Lung Cancer
Study Summary
This trial is testing a new combination therapy to see if it is effective and safe in treating non-small cell lung cancer.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2017 Phase 4 trial • 59 Patients • NCT02034474Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- My cancer has a mutation that can be treated with targeted therapy.I have pain from my cancer that isn't relieved by treatment.I can take care of myself and perform daily activities.I haven't had severe side effects from previous immunotherapy.My cancer has spread to my brain and is getting worse or hasn't been treated.I have or had cancer spread to the lining of my brain and spinal cord.I am 18 or older with advanced non-squamous NSCLC.I have a history of an autoimmune disease or idiopathic pulmonary fibrosis.I have undergone at least one treatment for my condition.I was treated with a checkpoint inhibitor before joining this trial.I am currently being treated for another type of cancer.
- Group 1: Atezolizumab and Tocilizumab
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Can you tell me if there is a history of Tocilizumab being used in other medical research studies?
"417 different clinical trials are currently underway to study Tocilizumab with 80 of them in Phase 3. The majority of research is being conducted out of Villejuif, Michigan; however, there are 2310 locations running studies for Tocilizumab."
Are there any current openings for volunteers in this trial?
"Unfortunately, this study is not currently enrolling patients. However, there are over 2000 other trials for cancer and Tocilizumab that are actively recruiting participants."
What are the conditions that Tocilizumab is used to manage?
"Tocilizumab is often used to treat small cell lung cancer (sclc), however it can also be taken as a prophylactic for other conditions like systemic juvenile idiopathic arthritis (sjia) and cytokine release syndrome caused by car-t cell therapy."
What makes this clinical trial different from others?
"Tocilizumab has been the focus of medical research for over a decade. The first trial was sponsored by Hoffmann-La Roche and took place in 2008. After this initial study, which recruited 720 patients, Tocilizumab received approval to enter Phase 2 clinical trials. In total, there are 417 ongoing studies involving Tocilizumab taking place in cities across 81 countries."
How many patients are taking part in this clinical trial?
"Unfortunately, this clinical trial is not currently looking for new patients. The study was originally posted on 1/1/2023 but was last edited on 7/18/2022. However, there are 2098 other trials actively enrolling patients with carcinoma and 417 trials involving Tocilizumab that are still recruiting participants."
Share this study with friends
Copy Link
Messenger